CoChat

Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer

Chiang, Pai-Kai, Tsai, Wei-Kung, Chiu, Allen Wen-Hsiang, Lin, Jhen-Bin, Yang, Feng-Yi, Lee, Jie · 2021 · Frontiers in Oncology
Cited by 35

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The changes in body composition are early adverse effects of androgen deprivation therapy (ADT); however, their prognostic impact remains unclear in prostate cancer. This study aimed to evaluate the association between body composition changes and survival in patients with high-risk prostate cancer. We measured the skeletal muscle index (SMI) and total adipose tissue index (TATI) at the L3 vertebral level using computed tomography at baseline and within one year after initiating ADT in 125 patients with high-risk prostate cancer treated with radiotherapy and ADT between 2008 and 2018. Non-cancer mortality predictors were identified using Cox regression models. The median follow-up was 49 months. Patients experienced an average SMI loss of 5.5% over 180 days (95% confidence interval: -7.0 to -4.0; p <0.001) and TATI gain of 12.6% over 180 days (95% confidence interval: 9.0 to 16.2; p <0.001). Body mass index changes were highly and weakly correlated with changes in TATI and SMI, respectively (Spearman ρ for TATI, 0.78, p <0.001; ρ for SMI, 0.27, p =0.003). As a continuous variable, each 1% decrease in SMI was independently associated with a 9% increase in the risk of non-cancer mortality (hazard ratio: 1.09; p =0.007). Moreover, the risk of non-cancer mortality increased 5.6-fold in patients with SMI loss ≥5% compared to those with unchanged SMI (hazard ratio: 5.60; p =0.03). Body mass index and TATI were not associated with non-cancer mortality. Muscle loss during ADT is occult, independent of weight change, and independently associated with increased non-cancer mortality in patients with high-risk prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2021.722652

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 40

  1. Nabid, 2018, Duration of Androgen Deprivation Therapy in High-Risk Prostate Cancer: A Randomized Phase III Trial, Eur Urol, 74, 10.1016/j.eururo.2018.06.018 · DOI · Paper page
  2. Lawton, 2017, Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202, Int J Radiat Oncol Biol Phys, 98, 296, 10.1016/j.ijrobp.2017.02.004 · DOI
  3. Saylor, 2013, Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer, J Urol, 189, S34, 10.1016/j.juro.2012.11.017 · DOI · Paper page
  4. Marvaso, 2021, Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches, Front Oncol, 11, 10.3389/fonc.2021.732766 · DOI
  5. Lee, 2005, Changes in Bone Mineral Density and Body Composition During Initial and Long-Term Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Carcinoma, Cancer, 104, 10.1002/cncr.21381 · DOI · Paper page
  6. Smith, 2012, Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer, J Clin Oncol, 30, 10.1200/JCO.2011.38.8850 · DOI · Paper page
  7. Nguyen, 2015, Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them, Eur Urol, 67, 10.1016/j.eururo.2014.07.010 · DOI · Paper page
  8. Owen, 2019, The Clinical Relevance of Adiposity When Assessing Muscle Health in Men Treated With Androgen Deprivation for Prostate Cancer, J Cachexia Sarcopenia Muscle, 10, 10.1002/jcsm.12446 · DOI
  9. Palumbo, 2021, Changes in Body Composition and Lipid Profile in Prostate Cancer Patients Without Bone Metastases Given Degarelix Treatment: The BLADE Prospective Cohort Study, Prostate Cancer Prostatic Dis, 24, 10.1038/s41391-021-00345-0 · DOI
  10. Suriano, 2020, Gut Microbiota and Regulation of Myokine-Adipokine Function, Curr Opin Pharmacol, 52, 9, 10.1016/j.coph.2020.03.006 · DOI
  11. McDonald, 2017, CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men With Prostate Cancer, Radiology, 282, 10.1148/radiol.2016160626 · DOI
  12. Huang, 2020, Prognostic Value of Muscle Measurement Using the Standardized Phase of Computed Tomography in Patients With Advanced Ovarian Cancer, Nutrition, 72, 110642, 10.1016/j.nut.2019.110642 · DOI
  13. Brown, 2018, The Evolution of Body Composition in Oncology-Epidemiology, Clinical Trials, and the Future of Patient Care: Facts and Numbers, J Cachexia Sarcopenia Muscle, 9, 10.1002/jcsm.12379 · DOI · Paper page
  14. Lee, 2018, Skeletal Muscle Loss Is an Imaging Biomarker of Outcome After Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer, Clin Cancer Res, 24, 10.1158/1078-0432.CCR-18-0788 · DOI
  15. Lee, 2019, Muscle Radiodensity Loss During Cancer Therapy Is Predictive for Poor Survival in Advanced Endometrial Cancer, J Cachexia Sarcopenia Muscle, 10, 10.1002/jcsm.12440 · DOI
  16. van Dijk, 2017, Low Skeletal Muscle Radiation Attenuation and Visceral Adiposity Are Associated With Overall Survival and Surgical Site Infections in Patients With Pancreatic Cancer, J Cachexia Sarcopenia Muscle, 8, 10.1002/jcsm.12155 · DOI · Paper page
  17. Huang, 2020, Muscle Loss During Primary Debulking Surgery and Chemotherapy Predicts Poor Survival in Advanced-Stage Ovarian Cancer, J Cachexia Sarcopenia Muscle, 11, 10.1002/jcsm.12524 · DOI
  18. Lee, 2021, Progressive Muscle Loss Is an Independent Predictor for Survival in Locally Advanced Oral Cavity Cancer: A Longitudinal Study, Radiother Oncol, 158, 10.1016/j.radonc.2021.02.014 · doi:10.1016/j.radonc.2021.02.014
  19. Kays, 2018, Three Cachexia Phenotypes and the Impact of Fat-Only Loss on Survival in FOLFIRINOX Therapy for Pancreatic Cancer, J Cachexia Sarcopenia Muscle, 9, 10.1002/jcsm.12307 · DOI
  20. Hua, 2021, Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy, Front Oncol, 11, 10.3389/fonc.2021.625534 · doi:10.3389/fonc.2021.625534
  21. Lee, 2021, Association of Patient-Reported Outcomes and Nutrition With Body Composition in Women With Gynecologic Cancer Undergoing Post-Operative Pelvic Radiotherapy: An Observational Study, Nutrients, 13, 2629, 10.3390/nu13082629 · DOI
  22. Caan, 2018, The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint, Cancer Res, 78, 10.1158/0008-5472.CAN-17-3287 · DOI · Paper page
  23. Lee, 2020, Muscle Loss After Chemoradiotherapy as a Biomarker of Distant Failures in Locally Advanced Cervical Cancer, Cancers (Basel), 12, 595, 10.3390/cancers12030595 · DOI
  24. Lee, 2018, The Effect of Body Mass Index and Weight Change on Late Gastrointestinal Toxicity in Locally Advanced Cervical Cancer Treated With Intensity-Modulated Radiotherapy, Int J Gynecol Cancer, 28, 10.1097/IGC.0000000000001312 · doi:10.1097/igc.0000000000001312
  25. Faron, 2020, Body Composition Analysis Using CT and MRI: Intra-Individual Intermodal Comparison of Muscle Mass and Myosteatosis, Sci Rep, 10, 11765, 10.1038/s41598-020-68797-3 · DOI · Paper page
  26. Newton, 2020, Timing of Exercise for Muscle Strength and Physical Function in Men Initiating ADT for Prostate Cancer, Prostate Cancer Prostatic Dis, 23, 10.1038/s41391-019-0200-z · DOI
  27. Di Maso, 2021, Adherence to Mediterranean Diet, Physical Activity and Survival After Prostate Cancer Diagnosis, Nutrients, 13, 243, 10.3390/nu13010243 · DOI
  28. Edmunds, 2020, The Role of Exercise in the Management of Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: A Rapid Review, Support Care Cancer, 28, 10.1007/s00520-020-05637-0 · DOI
  29. Bylow, 2008, Falls and Physical Performance Deficits in Older Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy, Urology, 72, 10.1016/j.urology.2008.03.032 · DOI · Paper page
  30. Alibhai, 2010, Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer, J Clin Oncol, 28, 10.1200/JCO.2010.29.8091 · DOI · Paper page
  31. Shahinian, 2005, Risk of Fracture After Androgen Deprivation for Prostate Cancer, N Engl J Med, 352, 10.1056/NEJMoa041943 · DOI · Paper page
  32. Sattar, 2021, Falls in Older Adults With Cancer: An Updated Systematic Review of Prevalence, Injurious Falls, and Impact on Cancer Treatment, Support Care Cancer, 29, 21, 10.1007/s00520-020-05619-2 · DOI
  33. Waterhouse, 2021, Vitamin D Supplementation and Risk of Falling: Outcomes From the Randomized, Placebo-Controlled D-Health Trial, J Cachexia Sarcopenia Muscle, 10.1002/jcsm.12759 · DOI
  34. Urquiza, 2020, Nutritional Status Is Associated With Function, Physical Performance and Falls in Older Adults Admitted to Geriatric Rehabilitation: A Retrospective Cohort Study, Nutrients, 12, 2855, 10.3390/nu12092855 · DOI
  35. Dautzenberg, 2021, Interventions for Preventing Falls and Fall-Related Fractures in Community-Dwelling Older Adults: A Systematic Review and Network Meta-Analysis, J Am Geriatr Soc, 10.1111/jgs.17375 · DOI · Paper page
  36. McCarthy, 2016, Diagnosis and Management of Vertebral Compression Fractures, Am Fam Physician, 94, 44
  37. Wilson, 2021, Using Exercise and Nutrition to Alter Fat and Lean Mass in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review, Nutrients, 13, 1664, 10.3390/nu13051664 · DOI
  38. Finkelstein, 2020, Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa318 · DOI
  39. Klotz, 2015, Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT, J Clin Oncol, 33, 10.1200/JCO.2014.58.2973 · DOI · Paper page
  40. Crawford, 2019, Androgen-Targeted Therapy in Men With Prostate Cancer: Evolving Practice and Future Considerations, Prostate Cancer Prostatic Dis, 22, 24, 10.1038/s41391-018-0079-0 · DOI · Paper page

Metadata

Authors
Chiang, P.-K., Tsai, W.-K., Chiu, A. W.-H., Lin, J.-B., Yang, F.-Y., & Lee, J.
Venue
Frontiers in Oncology
Published
2021-09-17
Volume
11
ISSN
2234-943X
Cited by
35
References
5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer. https://app.cochat.ai/papers/10.3389/fonc.2021.722652
The paper
Chiang, P.-K., Tsai, W.-K., Chiu, A. W.-H., Lin, J.-B., Yang, F.-Y., & Lee, J. (2021). Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer. Frontiers in Oncology. https://doi.org/10.3389/fonc.2021.722652

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.